Members of Paul Hastings’ Intellectual Property Litigation Practice are proud to speak at ACI’s Biosimilars and Innovator Biologics conference, taking place on June 22-23, 2021 virtually. The conference focuses on recent developments in litigation and regulations surrounding biosimilars and innovator biologics, and features invited speakers from the FDA, the FTC, the USPTO, and companies including Alexion Pharmaceuticals, Amgen, Eisai US, Fosun Pharma USA Inc., Genentech, Teva Pharmaceuticals, and more. Young J. Park, Partner, will participate on a panel “Advocating for Diversity in IP: Practical Ideas for Implementing Change.” Chad J. Peterman, Partner, will participate on the session “New Developments Impacting Professional Responsibility in the Biologic Arena.”